User:Mr. Ibrahem/Bazedoxifene

Mr. Ibrahem/Bazedoxifene
Clinical data
Pronunciation	ba" ze dox' i feen
Trade names	Conbriza, Viviant, others
Other names	Bazedoxifene acetate, TSE-424; WAY-140424; WAY-TSE-424
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
Routes of; administration	By mouth
Drug class	Selective estrogen receptor modulator (SERM)
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 1-[4-[2-(azepan-1-yl)ethoxy]benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol;
Chemical and physical data
Formula	C30H34N2O3
Molar mass	470.613 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1ccc(cc1)c3c(c2cc(O)ccc2n3Cc5ccc(OCCN4CCCCCC4)cc5)C;
	InChI InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3 ; Key:UCJGJABZCDBEDK-UHFFFAOYSA-N ;
	(what is this?) (verify)

Bazedoxifene, sold under the brand name Conbriza is a medication used to treat osteoporosis after menopause.^[2] It reduces the risk of spinal fractures but not hip fractures.^[2] It is taken by mouth.^[2]

Common side effects include hot flushes, muscle spasms, and swelling of the legs.^[2] Other side effects may include blood clots.^[2] It should not be used in pregnancy.^[2] It is a selective estrogen receptor modulator (SERM).^[2]

Bazedoxifene was approved for medical use in Europe in 2009.^[2] In the United States it is only available in combination as bazedoxifene/conjugated estrogens.^[1]

References[edit]

^ ^a ^b "Selective Estrogen Receptor Modulators". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 11 January 2022. Retrieved 8 January 2022.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l "Conbriza". Archived from the original on 6 January 2021. Retrieved 8 January 2022.